is contracted by means of direct inhalation of droplets or contaminated material. Rhinoscleroma usually affects the nasal cavity, but lesions can also be found on larynx, nasopharynx, oral cavity, paranasal sinuses, or soft tissues of the lips, nose, trachea, and bronchi. Nose is the most common site (95%-100%) [2] as seen in our case. It usually starts in the subepithelium of the nasal mucosa, spreading thereafter to other areas, such as the subepithelium of the pharynx, which is involved in 50% of cases. Extension to the oral cavity or oropharynx is seen in 18%-43% of patients. Factors predisposing are crowding, poor hygiene, poor nutrition, and intimate contact. [3] The disease most frequently affects persons in the 20-40 years of age range. These patients complain of nasal obstruction, rhinorrhea, epistaxis, dysphagia, nasal deformity, anesthesia of the soft palate, difficulty in breathing, stridor, dysphonia, and anosmia.
The disease manifests as three phases: exudative, proliferative, and fibrotic (cicatricial). The exudative phase presents as watery nasal discharge and crusting (catarrhal stage). The lesions evolve into noduloulcerative lesions involving the nose, upper lip, palate, and adjacent regions of the upper respiratory tract (granulomatous stage). With further progression of the disease, there is destruction of the nasal cartilages resulting in deformity (Hebra nose). This leads to fibrosis and subsequent obstruction (sclerotic stage). The differential diagnosis of rhinoscleroma includes vasculitis, lymphoma, extranodal Rosai-Dorfman disease, and nasal polyposis. [4] It is difficult to eradicate the disease and recurrences are common, and so, treatment of the disease poses a big challenge. In vitro studies have shown that clinically achievable concentrations of amoxicillin-clavulanate, chloramphenicol, trimethoprim-sulfamethoxazole, cephalosporins, streptomycin, tetracyclines, and ciprofloxacin inhibit the growth of Klebsiella rhinoscleromatis. Antibiotics such as streptomycin, doxycycline, tetracyclines, rifampicin, second-and third-generation cephalosporins, sulfonamides, and clofazimine have demonstrated their efficacy in vivo.
Some studies have suggested improvement in the disease with local application of rifampicin. [5] K. rhinoscleromatis being intracellular bacterium prolonged courses of rifampicin, and fluoroquinolones are also efficacious as these antibiotics achieve high concentrations in macrophages. [6] The total period for which antibiotic has to be administered is different in different studies; however, most conclude that long-term therapy for months and sometimes years is necessary to prevent relapses. [7] Comparison of various drugs used in the treatment of rhinoscleroma is depicted in Table 1 . Historically, tetracycline was preferred due to its low cost and efficacy. [10] However, doxycycline is better over tetracycline in terms of easy dosing, better patient compliance, and quicker response time. Currently recommended treatment regimen is a combination of ciprofloxacin and doxycycline for at least 6 months. Although combination therapy is preferred by some as relapse is seen commonly with this infection, ciprofloxacin monotherapy has shown excellent clinical efficacy and reports of cure with this drug also exist in literature. [11] The current case showed marked response to doxycycline monotherapy in terms of disappearance of symptoms and resolution of the lesions in 6 weeks.
COnClusiOn
Although tetracycline has been conventionally used for the treatment of rhinoscleroma, the lengthy duration of treatment (months to years) often leads to poor compliance and increased incidence of adverse events. Doxycycline monotherapy may be equally efficacious, may require lesser duration of treatment, and may have minimal compliance issues and fewer adverse events. Further research into the use of doxycycline monotherapy and trials comparing various antibiotics for this uncommon, but infectious condition would be of interest.
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